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ABSTRACT 
Disturbances of sodium and homeostasis have been shown to be important in 
salt-sensitive hypertension, hypertension and nephropathy associated with diabetes 
mellitus. In this project, the hypotheses that human erythrocyte ion transport systems 
have important pathophysiological roles in these conditions was considered. 
Previously established methodology was validated by myself and used to measure 
various erythrocyte ion transport systems. Several ion channel studies were performed 
on Chinese patients with hypertension and/or diabetes. A total of 127 Hong Kong 
Chinese attending the outpatient diabetes or hypertension clinics at the Prince of 
Wales Hospital, Shatin, Hong Kong were studied. 
The results showed that compared to control subjects, erythrocyte sodium-
lithium countertransport activity was increased in patients with essential hypertension, 
while lithium-potassium cotransport activity was similar between the two groups. 
There was no significant difference in erythrocyte intracellular sodium concentration 
between patients with essential hypertension and control subjects although there was 
a trend for erythrocyte intracellular sodium concentration to be higher in patients with 
essential hypertension. Furthermore, there was no significant difference in the 
erythrocyte passive potassium efflux between patients with essential hypertension and 
control subjects. 
Erythrocyte sodium-lithium countertransport activity was significantly higher 
in patients with non-insulin-dependent diabetes mellitus (NIDDM) compared to the 
control subjects. However, the increase in erythrocyte sodium-lithium 
countertransport activity have little relationship with hypertension or proteinuria 
among the NIDDM patients. There was a tendency for the erythrocyte lithium-
potassium cotransport activity to be higher in normotensive NIDDM patients 
compared to control subjects. Furthermore, erythrocyte intracellular sodium 
concentration was increased among the NIDDM patients. 
The antihypertensive agent, enalapril, an angiotensin converting enzyme 
inhibitor, induces a significant increase in both erythrocyte intracellular sodium 
concentration and lithium-potassium cotransport activity in hypertensive NIDDM 
patients. On the other hand, erythrocyte ion transport systems were not affected by 
nifedipine, a calcium channel blocking agent. 
These findings suggest that erythrocyte ion transport systems may play a role 
in the development of hypertension and NIDDM among the Chinese population. 
Furthermore, erythrocyte ion transport systems may be affected by some 
antihypertensive treatments. 
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Essential hypertension affects about 10-20% of the human population. The causes 
for essential hypertension appear to be multifactorial and include genetic and 
environmental factors. One major environmental factor contributing to the development 
of high blood pressure appears to be high sodium chloride intake. Studies at a molecular 
level have suggested that intracellular sodium and various cation transport systems may 
be important in the pathogenesis of essential hypertension (Aderounmu & Salako, 1979; 
Canessa et al, 1980a; Garay et al, 1980; Garay et al, 1987). These ion transport systems 
include the energy dependent sodium pump and other passive transport systems such as 
sodium-potassium-chloride cotransport, sodium-sodium countertransport (measured as 
sodium-lithium countertransport), and passive sodium and potassium fluxes. The 
intracellular sodium concentration represents the final outcome of the activities of these 
different sodium transport systems and other ion transport channels. Since erythrocytes 
are easily available and can be processed readily, they have been widely used for studies 
on cellular ion transport systems. 
Previous studies have demonstrated differences in ion transport systems between 
patients with essential hypertension and normotensive subjects although the results are 
controversial (Aderounmu (& Salako 1979; Canessa et al, 1980a; Garay et al, 1980; 
Canali et al, 1981; Cusi et al, 1981; Adragna et al, 1982a; Woods et al, 1982; Canessa 
et al, 1984b; Smith et al, 1984b; Weder et al, 1984; Wiley et al, 1984; Feig et al, 1985; 
Garay & Nazaret 1985; Krzesinski & Rorive, 1985b; Garay et al, 1987; Carr et al, 
1989). Genetic factors appear to influence certain ion transport systems (Garay et al, 
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1981b; Adragna et al, 1982b; Canessa et al, 1984a; Dadone et al, 1984; Weder, 1984; 
Kagamimori et al, 1985; Lewitter & Canessa, 1985; Carr et al, 1989) and differences 
in ion transport systems have been reported between normotensive Chinese, non-Chinese 
Asians and Europeans (Arumanayagam et al, 1987). The abnormalities in these systems 
did not appear to be the consequences of high blood pressure per se (Canessa et al, 
1980a; Dagher & Garay 1980; Duhm & Behr 1986; Weder, 1990) but rather represent 
individual predispositions for the development of essential hypertension. 
The incidence of diabetes mellitus has markedly increased in the last fifty years. 
Classically this disease is divided into insulin-dependent diabetes mellitus (IDDM) and 
non-insulin-dependent diabetes mellitus (NIDDM). It has been suggested that there are 
close associations between the genetic factors predisposing individuals to the development 
of both essential hypertension and diabetes mellitus (Weidmann & Ferrari, 1991; 
Weidmann etal, 1991). Furthermore, the genetic predisposition for essential hypertension 
may also be a risk factor for the development of nephropathy in patients with diabetes 
mellitus. Previous studies have shown that there were abnormalities of ion transport 
systems in patients with diabetes mellitus (Krokewski et al, 1988; Mangili et al, 1988; 
Carr et al, 1990a; Trevisan et al, 1990; Walker et al, 1990; Gall et al, 1991; Zerbini, 
1991). 
Therefore, in this project, the aim is to study the erythrocyte ion transport 
systems in Chinese patients with essential hypertension and their possible 
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pathophysiological roles in these conditions. In this study, the significance of the ion 
transport systems in Chinese patients with NIDDM will also be examined. In addition, 
the effects of some commonly used antihypertensive agents, such as the angiotensin 
converting enzyme inhibitors and calcium channel blockers, on the various ion transport 





2.1 ION TRANSPORT SYSTEMS IN HUMAN ERYTHROCYTES 
Human erythrocytes have been widely used for studies on cellular ion 
transport systems. Sodium movements across erythrocyte membranes are 
facilitated by several transport systems which include the energy dependent 
sodium pump (Na+ K+-ATPase) and other passive sodium transport systems 
such as the sodium-potassium-chloride cotransport, sodium-sodium 
countertransport (measured as sodium-lithium countertransport), and passive 
sodium and potassium fluxes. 
2.1.1 Sodium Pump (Na+ K^-ATPase) 
Under physiological conditions, human erythrocytes, like other cells, 
have low intracellular sodium and high potassium concentrations as compared 
to the extracellular fluids. The intracellular concentrations of sodium and 
potassium in the erythrocytes are maintained mainly by the ATP-dependent 
sodium pump (Kaplan, 1985; Skou, 1988). 
The sodium pump has been identified as a trans-membrane ATP-
hydrolysing enzyme system. This enzyme is activated by sodium on the 
cytoplasmic side and potassium on the extracellular side of the membrane in 
the presence of magnesium and hence is called 'sodium, potassium-stimulated 
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magnesium dependent adenosine triphosphatase (Na+ K+-ATPase) . This 
enzyme-catalysed active transport system is ubiquitous although the activity of 
the sodium pump varies between cell types (Kaplan, 1985; Skou, 1988). 
The main function of the sodium pump is to actively transport sodium 
out of the cell and potassium into the cell against electrochemical gradients. 
The energy required for this process comes from the hydrolysis of ATP. 
Physiologically, this transport system catalyses the exchange of three 
intracellular sodium ions for two extracellular potassium ions coupled with the 
hydrolysis of ATP (Figure 2.1; Kaplan, 1985; Skou, 1988). As a result of the 
sodium pump activity, an electrochemical gradient can be generated across 
cellular membranes. This gradient is essential in order to facilitate the function 
of other ion transport systems, such as the sodium-hydrogen exchange system, 
sodium-calcium cotransport system and sodium-noradrenaline cotransport 
system. The activities of these transport systems, which are often cell type 
dependent, will provide the milieu necessary for the different cellular functions 
(Mahnensmith & Aronson 1985). 
The sodium pump is stimulated by the addition of potassium to the 
extracellular fluid and sodium to the intracellular fluid. Conversely, the pump 
is inhibited by lowering the extracellular potassium concentration or the 
intracellular sodium concentration. A variety of plant glycosides have been 
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shown to inhibit the sodium pump, such as ouabain, digoxin, vanadate, and 
oligomycin (Wallick & Schwatz 1988; Beauge, 1988; Skou, 1988). The 
cytoplasmic sites approach complete saturation when the intracellular sodium 
and potassium concentrations are 130 and 20 mmol/1 cell, respectively. Within 
the range of the physiological intracellular concentration of sodium (10 mmol/1 
cell) and potassium (160 mmol/1 cell), the sodium pump is operating at about 
30-40% of its maximal capacity (Haddy, 1983; Kaplan, 1985; Skou, 1988). 
2.1,2 Passive Sodium Transport Systems 
In addition to the ATP-dependent sodium pump, there are other minor 
sodium transport systems which do not require the hydrolysis of ATP. 
2.1.2.1 Sodium-potassium-chloride cotmnsport system 
Evidence for the existence of a sodium-potassium-chloride cotransport 
system in human erythrocytes have been accumulating for several years. This 
transport system is present in a wide variety of tissues and serves a number of 
physiological functions. Hoffman and Kregenow (1966) first described ouabain 
resistant net uphill sodium extrusion from human erythrocytes. They called this 
pathway 'pump IF and suggested that it might be mediated by some form of 
the ATP-dependent sodium pump. Sachs (1971) extended their observations 
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and showed that this net outward movement of sodium could be inhibited by 
external potassium and frusemide. Beauge and Adragna (1971) reported 
stimulation of ouabain resistant potassium influx into human erythrocytes by 
external sodium. Wiley and Cooper (1974) subsequently demonstrated that 
ouabain-resistant sodium influx was higher in the presence of external 
potassium and also that ouabain-resistant potassium influx was stimulated by 
external sodium. These findings confirmed the presence of the cotransport 
system and suggested that it is a carrier-mediated transport system. 
This cotransport system has multiple modes of action involving the 
coupled movements of sodium, potassium, and chloride in both inward and 
outward directions across the cell membranes (Figure 2.2; Canessa et al, 
1986a; Canessa, 1989). Furthermore, chloride is essential for the operation of 
the cotransport system (Chipperfield, 1986; Canessa, 1989). The stoichiometry 
of net sodium, potassium, and chloride movement is 1:1:2 (Canessa et al, 
1986a; Chipperfield, 1986). In erythrocytes with a physiological intracellular 
sodium concentration, the cotransport system does not catalyze any net sodium 
movement. However, a moderate increase or decrease in the intracellular 
sodium concentration will stimulate the cotransport system. The latter responds 
to sodium excess with maximal sodium extrusion and to sodium depletion with 
maximal sodium entry (Gamy et al, 1983; Canessa, 1989). It was also found 
that outward movement by the sodium-potassium-chloride cotransport system 
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was maximally activated when the sodium and potassium concentrations were 
90 and 20 mmol/1 cell, respectively (Garay et al, 1981a). Furthermore, sodium 
and potassium can be replaced by other cations in the cotransport system. 
Lithium can substitute for sodium and rubidium can substitute for potassium 
in the cotransport system (Canessa et al, 1982; Smith et al, 1984a; 
Chipperfield, 1986). In contrast, no anion has been found to substitute for 
chloride in this cotransport system (Chipperfield, 1986). 
Sodium-potassium-chloride cotransport is a passive process. There is 
no direct consumption of energy in any form of ATP (Geek et al, 1980) and 
no corresponding chloride-dependent ATPase (Gerencser & Lee, 1983). 
However, the exact mechanism of modulation has not yet been defined. 
Sodium-potassium-chloride cotransport is ouabain-resistant but can be inhibited 
by loop diuretics in descending order of affinity: bumetanide > piretanide > 
frusemide (Palfrey et al, 1980; Ellory & Stewart 1982). 
Physiologically, the sodium-potassium-chloridecotransport system plays 
a role in the regulation of cell volume and in the homeostasis of intracellular 
potassium concentration. Another function of the cotransport system is to 
maintain the high chloride concentration in vascular smooth muscle cells. It is 
also an important cation regulator in tissues such as the kidney tubule, vascular 
endothelium, and smooth muscle. The intracellular chloride concentration 
12 
determines the direction of the net cation and chloride movement across the 
cellular membranes via the cotransport system. The activity of sodium-
potassium-chloride cotransport can be modulated by several vasoactive 
substances such as cyclic AMP, bradykinin, vasopressin, atrial natriuretic 
factor (ANF), and growth factors. The effects of these hormones and growth 
factors on the cotransport system appear to be tissue-specific (Chipperfield, 
1986; Canessa et al, 1987; Canessa, 1989). In fact, cyclic AMP inhibits the 
sodium-potassium-chloride cotransport system in vascular smooth muscle and 
endothelial cells, while bradykinin and vasopressin markedly stimulate it 
(Owen, 1985; Shoemaker et al, 1985). O'Donnell and Owen (1986) reported 
that vasorelaxant ANF stimulates inward cotransport of potassium into vascular 
smooth muscle. The activation of the transporter in this case is mediated by 
the second messenger, cGMP. However, in other tissues, ANF and cGMP 
inhibit this cotransport system. The exact role of this pathway in erythrocyte 
is not known. (Rao et al, 1984; O'Grady et al, 1985). 
2.1.2.2 Sodium-lithium Countertransport 
Lithium salts are effective in the treatment of mania and have been used 
for preventing or reducing the rates of relapse and recurrence of manic or 
depressive episodes in bipolar affective disorders. In clinical studies, it was 
found that the erythrocyte intracellular lithium concentrations of these patients 
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was only one-third of that in plasma (Mendels & Frazer 1973). These 
observations led to the suggestion of the possible presence of an 'uphill' 
extrusion mechanism for lithium. Haas et al reported the presence of an 
ouabain-resistant sodium-lithium countertransport system in 1975 which 
extruded lithium against a concentration gradient in normal human 
erythrocytes. This observation was also reported independently by Duhm et al 
(1976). 
Sodium-lithium countertransport in human erythrocytes is a coupled 
exchange between sodium and lithium (Figure 2.1). The system performs a 1:1 
exchange of sodium and lithium across the erythrocyte membrane. It has been 
suggested that the countertransport system is carrier-mediated (Hass et al, 
1975; Duhm et al, 1976; Sarkadi et al, 1978). Sodium-lithium countertransport 
is ouabain-resistant but can be inhibited by phloretin, frusemide, quinine, and 
quinidine. It does not require the presence of ATP but is sodium-dependent. 
Lithium movements into or out of the erythrocytes are stimulated by sodium 
on the trans (opposite) side and inhibited by sodium on the cis (same) side of 
the membrane. No other cation can substitute for sodium in this role. (Pandey 
et al, 1978). The internal sodium and lithium concentrations at which the 
velocity of the countertransport is half maximal activated (KJ are 9.0 and 0.5 
mmol/1 cell, respectively, while the external sodium and lithium concentrations 
are 25 and 1.5 mmol/1, respectively (Sarkadi et al, 1978). 
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In the absence of lithium and under physiological conditions, the 
erythrocyte sodium-lithium countertransport mediates 1:1 sodium-sodium 
exchange (Duhm & Becker, 1979; Mahnensmith & Aronson, 1985; 
Weinberger et al, 1989). There are many similarities between the sodium-
lithium and sodium-hydrogen countertransport systems, such as the mediation 
of 1:1 electroneutral monovalent cation exchange, the lack of ATP hydrolysis, 
the use of downhill cation gradients to drive the transporter, and ouabain 
insensitivity. Both systems also possess affinities for sodium, lithium, and 
hydrogen exhibiting a higher affinity for lithium than sodium. Neither of these 
two systems has affinity for choline, cesium, rubidium, or potassium. Both 
systems can operate in a sodium-sodium exchange mode. External hydrogen 
interacts competitively with sodium-lithium countertransport in a manner 
similar to the way external lithium interacts competitively with sodium-
hydrogen countertransport (Aronson, 1982; Funder et al, 1984; Mahnensmith 
& Aronson, 1985; Canessa et al, 1987). In addition, sodium-hydrogen 
countertransport, like sodium-lithium countertransport, has been demonstrated 
in the erythrocytes of other mammals (Dissing & Hoffman, 1982; Parker, 
1983). Aronson (1982) and Funder et al (1984) suggested that sodium-lithium 
countertransport may just represent a functional mode of plasma membrane 
sodium-hydrogen countertransport. Despite these similarities, there are 
important differences between the sodium-lithium and sodium-hydrogen 
countertransport systems. Sodium-lithium countertransport activity is inhibited 
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by phloretin, whereas sodium-hydrogen countertransport is not (Escobales & 
Canessa, 1986). Sodium-hydrogen countertransport is sensitive to amiloride, 
while sodium-lithium countertransport is amiloride resistant (Escobales & 
Canessa, 1986; Kahn, 1987). However, Escobales and Canessa (1986) 
reported that only 30-50% of human erythrocyte sodium-hydrogen 
countertransport was amiloride sensitive. Canessa et al (1987) and Kahn et al 
(1989) suggested that the sodium-lithium and sodium-hydrogen 
countertransport systems were mediated by the same transporter. 
Sodium-hydrogen countertransport plays important physiological roles 
in the regulation of intracellular Ph, the control of cell growth and 
proliferation, stimulus-responsive coupling in leucocytes and platelets, the 
metabolic responses to hormones such as insulin and glucocorticoids, the 
regulation of cell volume, and the trans-epithelial absorption and secretion of 
sodium, hydrogen, bicarbonate, chloride, and organic anions. In these regards, 
its operation is further modulated by intracellular hydrogen and possibly by 
intracellular calcium concentration (Aronson, 1982; Mahnensmith & Aronson 
1985; Huot & Aronson 1991). 
2,1.3 Ouabain- and Frusemide-Resistant Passive Effluxes 
The ouabain and frusemide resistant sodium and potassium effluxes 
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(i.e. the sodium and potassium leak) from the erythrocytes are defined as the 
residual effluxes of sodium and potassium following inhibition of the sodium 
pump and sodium-potassium-chloride cotransporter, by ouabain and frusemide, 
respectively. These ouabain and frusemide resistant sodium and potassium 
effluxes represent the ground cation permeability of the erythrocyte membrane 
(Lew & Beauge, 1979; Maridonneu et al, 1983; Garay & Nazaret, 1985). 
Under these experimental conditions, the effluxes show no saturation with 
increases in the internal concentrations of the two ions. Both sodium and 
potassium effluxes are therefore linear functions of the internal sodium and 
potassium concentrations respectively and are independent of external sodium 
and potassium concentrations. The rate constants of sodium and potassium 
efflux are calculated as ratios corrected for intracellular sodium and potassium 
concentrations (Garay et al, 1981a). 
2.2 ERYTHROCYTE SODIUM TRANSPORT SYSTEMS IN ESSENTIAL 
HYPERTENSION 
Essential hypertension affects about 10-20% of the population. The 
causes for hypertension appear to be multifactorial and include genetic 
determinants as well as environmental factors, such as a high sodium chloride 
intake. In recent years, studies on sodium transport in the erythrocytes of 
hypertensive patients and their relatives suggest that abnormalities in their 
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cation exchange systems may be important in the development of essential 
hypertension. 
J Sodium Pump (Na+ K^-ATPase) in Essential Hypertension 
One major environmental factor contributing to the onset of essential 
hypertension is high sodium intake. Excessive sodium intake tends to induce 
vascular volume expansion which may stimulate the release of natriuretic 
hormones. These include atrial natriuretic factor (ANF), which is a peptide 
present in specific granules of the atrial cardiocytes, and the endogenous 
ouabain-like factor (digoxin-like substance), which is thought to be a small 
molecule and produced from the hypothalamus (DeWardener, 1985; Garay et 
al, 1987; Buckalew & Paschal-McCormick 1989; Hamlyn 1989). The sites 
of action of ANF include the renal glomeruli where it increases glomerular 
filtration rate and promotes natriuresis (Atlas et al, 1984). 
Physiologically, reabsorption of sodium in the renal tubules depends on 
the concentration gradient across the luminal membrane of the renal tubular 
cells. The intracellular sodium concentration of the tubular cells is lower 
compared with that of the luminal fluid. This low intracellular concentration 
of sodium in the tubular cells is maintained by the activity of the sodium pump 
in the basolateral membrane. These allow passive diffusion from the luminal 
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fluid into the tubular cells. In the presence of the ouabain-like factor, the 
activity of the sodium pump is inhibited. This leads to the accumulation of 
sodium within the tubular cells which reduces the concentration gradient across 
the tubular cellular membrane. The resulting reduction in sodium reabsorption 
by the tubular cells leads to natriuresis. In addition, the sodium pump 
promotes natriuresis through the generation of an electrochemical gradient 
across the renal tubular cellular membrane which facilitates the activity of the 
sodium-hydrogen countertransport system. The latter performs a 1:1 exchange 
of internal hydrogen for external sodium ions. These dual processes allow the 
excretion of hydrogen and reabsorption of bicarbonate and sodium from the 
renal tubules. Inhibition of sodium pump activity consequently facilitates 
natriuresis by decreasing the activity of sodium-hydrogen exchange and 
reducing the sodium concentration gradient across the cellular membrane, 
resulting in an overall reduction of sodium reabsorption from the renal tubules 
(Mahnensmith & Aronson 1985). 
In blood vessels, inhibition of sodium pump activity by the ouabain-like 
factor increases the intracellular sodium concentration and leads to 
depolarization of the vascular smooth muscle cells. This increases the 
membrane permeability to extracellular calcium ions by opening the sodium-
calcium exchanger resulting in calcium influx. The increased intracellular 
calcium concentration causes contraction of the vascular smooth muscle cells 
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giving rise to vasoconstriction. In the heart, inhibition of the sodium pump also 
increases the intracellular sodium concentration in cardiac muscle. This 
reduces the activity of the sodium-calcium exchanger in the plasma membrane 
of the myocardial cell, which normally moves sodium ions into the cell and 
calcium ions out of the cell. The resultant accumulation of calcium inside the 
myocardial cells increases the contractility of the heart. Thus, the ouabain-like 
factor stimulates the heart, constricts the blood vessels, and increases sodium 
and water excretion by the kidney. The later may lower the plasma volume to 
a normal level. However, the penalty for the release of the ouabain-like factor 
is the development of high blood pressure due to the simultaneous increase in 
the contractility of the heart and in the peripheral vascular resistance 
(Blaustein, 1977; Blaustein & Hamlyn 1983; DeWardener, 1985; Garay etal, 
1987; Figure 2.3). In this context it is noteworthy that, decreased erythrocyte 
sodium pump activities have been reported in about 5-15% of patients with 
essential hypertension (Diez et al, 1987; Garay et al, 1987). 
2.2.2 Sodium-Potassium-Chloride Cotransport in Essential Hypertension 
Abnormally low outward chloride dependent sodium-potassium 
cotransport was first reported by Garay et al (1980) in erythrocytes from 
patients with essential hypertension and confirmed by Cusi et al (1981) and 
Smith et al (1984b). The low activity of the chloride dependent sodium-
20 
potassium cotransport system may be due to an increased for outward 
cotransport of sodium (Garay et al, 1983). However, these findings are 
controversial and there are great inter-individual variations among both 
normotensive and hypertensive subjects. Furthermore, reduced, normal, or 
increased erythrocyte sodium-potassium cotransport activities have all been 
reported in patients with essential hypertension (Adragna et al, 1982a; Smith 
et al, 1984b; Wiley et al, 1984; Feig et al, 1985; Krzesinski & Rorive, 
1985a). Overall, decreased activity of outward sodium-potassium-chloride 
cotransport in erythrocytes has been found in about 25-35% of patients with 
essential hypertension (Garay et al, 1987). 
On the other hand, a normal outward chloride dependent sodium-
potassium cotransport has been found in patients with secondary hypertension 
who have no family history of hypertension, suggesting that abnormal 
cotransport is not a consequence of high blood pressure per se (Dagher & 
Garay, 1980). Furthermore, there appears to be a familial influence on 
sodium-potassium-chloride cotransport (Adragna et al, 1982b; Canessa et al, 
1984a; Kagamimori et al, 1985; Lewitter & Canessa, 1985). Abnormally low 
chloride-dependent sodium-potassium cotransport has been reported in 
normotensive subjects born of hypertensive parents and normotensive subjects 
with low sodium-potassium cotransport activity are at increased risk of 
developing of essential hypertension (Dagher & Garay 1980; Cusi et al, 1981). 
2 1 
Figure 2.3: The diagram of how an inherited defect in renal sodium excretion may lead 
to inhibiti~n of sodium transporl in erythrocyte, leucocyte, sympathetic neurons, and 
vascular smooth muscle. These effects appear to be mediated by a circulating 
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Studies on inward cotransport have shown that it is not altered in patients with 
hypertension (Duhm et al, 1982; Wiley et al, 1984; Bin Talib et al, 1984). 
Several studies have shown that the activity of outward sodium-
potassium-chloride cotransport is lower in blacks than in whites (Garay et al, 
1981b; Weder et al, 1984; Canessa et al, 1984b). Furthermore, sodium intake 
can modulate the erythrocyte sodium-potassium-chloride cotransport activity. 
Reduction of sodium intake from 200 to 100 mEq/day increases the outward 
sodium-potassium cotransport activity in some patients with hypertension 
(Canessa, 1989; Canessa et al, 1989). On the other hand, young blacks with 
a low outward sodium-potassium-chloride cotransport activity are more likely 
to increase their blood pressure after salt loading (Canessa et al, 1986b; 
Canessa et al, 1990). 
2.2.3 Sodium-Lithium Countertransport in Essential Hypertension 
In 1980 Canessa et al first described an association between essential 
hypertension and elevated erythrocyte sodium-lithium countertransport activity 
in vitro (Canessa et al, 1980a). This observation has also been confirmed by 
other investigators suggesting the involvement of abnormally high sodium-
lithium countertransport activity in the pathogenesis of essential hypertension 
(Canali et al, 1981; Aronson, 1982; Woods et al, 1982; Mahnensmith & 
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Aronson 1985; Carr et al, 1989). Increased activity of erythrocyte sodium-
lithium countertransport has been reported in 25-35% of patients with essential 
hypertension (Garay et al, 1987) while erythrocyte sodium-lithium 
countertransport activity was normal in cases of secondary hypertension 
(Canessa et al, 1980a; Weder, 1990). The exception is hyperaldosteronism, 
where hypokalemia may play a stimulatory role (Beuckelmann et al, 1985; 
Duhm & Behr, 1986). Sodium-lithium countertransport appears to be highly 
inheritable (Dadone et al, 1984; Weder, 1990) and increased activity of this 
transporter has been reported in normotensive relatives of patients with 
essential hypertension (Canessa et al, 1980a; Canali et al, 1981; Woods et al, 
1982; Carr et al, 1989). Individuals with increased erythrocyte sodium-lithium 
countertransport activity may increased risk of developing hypertension (Weder 
& Schork 1989; Hunt et al, 1991; Weder et al, 1991). Sodium-lithium 
countertransport may be a functional mode of sodium-hydrogen 
countertransport (see section 2.1.2.2). Figure 2.4 is a schematic model 
illustrating the mechanisms by which increased sodium-hydrogen exchange 
could contribute to the development of hypertension. 
Canessa et al (1980b) reported that alteration of salt balance did not 
affect erythrocyte sodium-lithium countertransport activity which has been 
confirmed by other investigators (Cooper et al, 1984; Krzesinski & Rorive 
1985b; Canessa et al, 1989). However, Weder (1991) showed that those 
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Figure 2.4: Flow diagram showing ways in which increased sodium-hydrogen exchange 
activity i~ vascular smooth muscle cells and renal proximal tubule cells could 
contribute to development of hyperlension. pH;=intracellular pH (from Huot & 
Aronson, 1991). 
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patients who demonstrated the greatest degree of elevation of blood pressure 
in response to a salt load, had significantly higher basal erythrocyte sodium-
lithium countertransport activity. 
2 .4 Passive Ion Fluxes in Essential Hypertension 
There are few reports on erythrocyte ouabain and frusemide resistant 
passive potassium efflux in hypertension. Aderounmu & Salako (1979) found 
that the passive potassium efflux was lower in hypertensive patients compared 
to the normotensive subjects. On the other hand, erythrocyte ouabain- and 
frusemide-resistant passive sodium influx was increased in about 15-25% of 
patients with essential hypertension (Garay & Nazaret 1985; Garay et al, 
1987). 
2.2.5 Intracellular Sodium Concentration in Essential Hypertension 
The intracellular sodium concentration in erythrocytes represents the 
final outcome of the activities of all membrane sodium transport systems and 
channels. The basal erythrocyte sodium concentration depends on the balance 
between sodium entry due to passive sodium influx and other gradient 
dissipators as well as sodium extrusion by the sodium pump (Garay et al, 
1983; Garay et al, 1987). Elevated erythrocyte intracellular sodium 
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concentrations have been found in patients with essential hypertension 
(Aderounmu & Salako 1979; Zidek et al, 1985; Rahman et al, 1986; Persky 
et al, 1990) and the normotensive first degree relatives of hypertensive 
individuals suggesting that genetic factors are important in the determination 
of erythrocyte intracellular sodium concentration (Lijnen et al, 1984; Hasstedt 
et al, 1988). In this regard, erythrocyte intracellular sodium concentration has 
been reported to be higher amongst the blacks than whites (Smith et al, 1988; 
Persky et al, 1990). 
2.3 ERYTHROCYTE SODIUM TRANSPORT SYSTEMS IN DIABETES 
MELLITUS 
Some evidence suggests that a genetic predisposition for essential 
hypertension may increase the risk of developing diabetic nephropathy in 
patients with diabetes. While the onset of diabetic nephropathy will aggravate 
the severity of hypertension, hypertension itself further promotes the 
progression of nephropathy in diabetic patients. In insulin-dependent diabetes 
mellitus (IDDM) blood pressure is usually normal in the absence of 
nephropathy, but increases with the development of nephropathy. On the other 
hand, in non-insulin-dependent diabetes mellitus (NIDDM), hypertension may 
either precede, coexist or develop after the onset of nephropathy (Fuller, 1985; 
Felicetta & Sowers 1988; Weidmann & Ferrari, 1991; Weidmann et al, 
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1991). 
Krolewski et al (1988) and Mangili et al (1988) reported that 
erythrocyte sodium-lithium countertransport activity was increased in patients 
with IDDM and nephropathy. In another studies, Carr et al (1990a) and 
Zerbini (1991) reported that those IDDM patients with increased erythrocyte 
sodium-lithium countertransport activity may be at risk of developing 
nephropathy. Furthermore, IDDM patients with increased erythrocyte sodium-
lithium countertransport activity have a higher incidence of diabetic 
nephropathy and hypertension in their families (Walker et al, 1990). These 
studies suggest that a genetic predisposition to hypertension, as reflected in 
increased erythrocyte sodium-lithium countertransport activity, may be a 
marker for the development of nephropathy in patients with IDDM. 
In addition, it has been reported that erythrocyte sodium-lithium 
countertransport activity was higher in Caucasian patients with NIDDM 
compared with non-diabetic control subjects irrespective of the presence of 
hypertension or nephropathy (Trevisan et al, 1990; Gall et al, 1991). Johnson 
et al (1990) also found higher sodium-lithium countertransport activity in black 
hypertensive NIDDM patients compared with black normotensive control 
subjects. On the other hands, chloride dependent sodium-potassium cotransport 
activity was found to be similar between NIDDM patients (with and without 
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hypertension) and non-diabetic control subjects (Trevisan et al, 1988). 
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CHAPTER 3 
MATERIALS & METHODS 
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The methodology for determination of ion transport systems in this study was 
developed by Dr Mano Arumanayagam, lecturer in the Department of Chemical 
Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, 
Hong Kong (1990). 
3.1 MATERIALS 
Tris [tris hydroxymethyl aminomethane (Trizma-base)] MOPS 
(morpholinopropane sulphonic acid), 2,5-p-chloromercuribenzene sulphonate 
(pCMBS), choline chloride, glucose, ouabain, magnesium chloride, sodium 
chloride, lithium chloride, haemoglobin standard, and Drabkin's reagent were 
obtained from Sigma Chemical Co, USA. Bumetanide was a kind gift from 
Jebsen & Co Ltd (agents for LEO pharmaceutical). 
The reagents used for the various experiments are described in the 
following sections. 
3.1.1 Choline Wash Solution (CWS) 
Choline Wash Solution contains choline chloride (149 mmol/1), 
magnesium chloride (1 mmol/1), Tris-MOPS (10 mmol/1, Ph 7.4) and glucose 
(10 mmol/1). 
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Lithium Loading Solution 
Lithium Loading Solution contains lithium chloride (15 mmol/1), Tris-
MOPS (10 mmol/1, pH 7.4), and glucose (10 mmol/1). 
3 3 Choline Wash Solution with Ouabain (CWS-0) 
Choline Wash Solution with Ouabain contains choline chloride (149 
mmol/1) magnesium chloride (1 mmol/1), Tris-MOPS (10 mmol/1, pH 7.4) 
glucose (10 mmol/1), and ouabain (0.1 mmol/1). 
3.1.4 Sodium Containing Medium (SCM) 
Sodium Containing Medium contains choline chloride (149 mmol/1), 
sodium chloride (145 mmol/1), magnesium chloride (1 mmol/1), glucose (10 
mmol/1), Tris-MOPS (10 mmol/1, pH 7.4), and ouabain (0.1 mmol/1). 
3.1.5 Sodium Free Medium (SFM) 
Sodium Free Medium contains choline chloride (149 mmol/1), 
magnesium chloride (1 mmol/1), glucose (10 mmol/1), Tris-MOPS (10 mmol/1, 
pH 7.4), and ouabain (0.1 mmol/1). 
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Sodium Free Medium with Bumetanide (SFM-B) 
Sodium Free Medium with Bumetanide contains choline chloride (149 
mmol/1) magnesium chloride (1 mmol/1) glucose (10 mmol/1), Tris-MOPS 
(10 mmol/1, pH 7.4), ouabain (0.1 mmol/1), and bumetanide (0.02 mmol/1). 
3.1,7 Preservation Solution 
Preservation Solution contains potassium chloride (145 mmol/1), 
magnesium chloride (10 mmol/1), Tris-MOPS (10 mmol/1, pH 7.5), and 
glucose (5 mmol/1). 
3.2 STUDY POPULATION 
A total of 127 Chinese patients attending the outpatient diabetes or 
hypertension clinics of the Prince of Wales Hospital, Shatin, Hong Kong were 
recruited for a number of projects relating to hypertension and NIDDM which 
had all been approved by the Clinical Research Ethical Committee, Faculty of 
Medicine, the Chinese University of Hong Kong. The patients recruited from 
the hypertension clinic were asked to discontinue their antihypertensive 
medications, if prescribed, for at least 2 weeks before coming for investigation 
to the Clinical Pharmacology Study Unit (CPSU). Only NIDDM patients 
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treated with diet or oral hypoglycaemic agents, or both were studied. 
Normotensive NIDDM patients were directly recruited from the diabetes clinic 
while the hypertensive NIDDM patients were recruited from a clinical trial 
comparing enalapril or nifedipine. Some of these trial patients were also 
receiving diuretic therapy and all had been previously recruited from the 
diabetic clinic. 
All subjects were maintained on their usual diets. Except for the 
hypertensive NIDDM patients who had already been established on their 
antihypertensive treatment for at least one year, all other subjects attended the 
CPSU on at least three occasions to have their blood pressures documented. 
All patients attended the CPSU in the fasting state on the study day when 
venous blood was sampled for the measurements of routine biochemistry and 
the indices used to evaluate the erythrocyte sodium transport systems. A total 
of 2 ml of blood was transferred to EDTA tubes for determination of the full 
blood count. The remainder was placed into two lithium heparin tubes and kept 
on ice until the plasma had been separated. The patients with diabetes were 
also asked to collect a 24 hour urine sample for estimation of their urinary 
excretion of albumin and electrolytes. Urinary infection was excluded by 
examination and culture of a mid-stream urine specimen. 
Among the hypertensive NIDDM patients who were in the clinical trial, 
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a subset receiving monotherapy with enalapril or nifedipine were asked to 
discontinue their medications for 2 weeks. Routine biochemistry and indices 
for evaluation of erythrocyte sodium transport systems were examined before 
and after the withdrawal of treatment. 
Blood pressure was measured by a research nurse using a Hawksley 
random zero sphygmomanometer after the patient had rested for 5 minutes in 
the supine position and after 2 minutes of standing. The patients recruited from 
the diabetes or hypertension clinics, were considered to be normotensive if the 
supine systolic blood pressure was < 140 mmHg and diastolic blood pressure 
^ 90 mmHg (phase V) on at least 3 separate occasions including the study 
day. Patients who had supine blood pressure > 140/90 mmHg on at least 3 
separate occasions including the study day were considered to be hypertensive. 
All urine samples were stored at 4 C and analysed within 1 week of 
collection for albumin concentration by immunoturbidimetry (Cheung & 
Swaminathan, 1989). Intra-assay and inter-assay coefficients of variation were 
3.3% and 6.7% respectively within the range 1.2-80 mg/l. The lowest 
detection limit was 1.2 mg/l. Plasma and urine creatinine concentrations were 
measured by the Jaffe method on a Beckman Astra-8 Chemistry Analyser 
(Beckmen Instrument Inc, Palo Alto, CA USA). Plasma glucose concentration 
was measured by a glucose oxidase method (Diagnostic Chemicals Ltd reagent 
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kit). Glycosylated haemoglobin (HbAO was measured by gel electrophoresis 
(Ciba Corning Diagnostics Corp, Palo Alto, CA, USA). The methodology for 
the evaluation of the various sodium transport systems will be described in 
detail later. 
3.2.1 Control Subjects 
Of the subjects recruited from the hypertension clinic, 13 subjects (6 
males 7 females) were found to have a normal supine blood pressure (systolic 
blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg) and 
normal fasting plasma glucose concentration ( < 7.8 mmol/1). These subjects 
were selected as the control subjects. 
3.2.2 Patients with Essential Hypertension 
A total of 19 patients (7 males, 12 females) were considered to have 
essential hypertension based on a supine blood pressure > 140/90 mmHg on 
at least three occasions including the study day and no evidence of renal or 
endocrine disease or other cause of secondary hypertension. All these patients 
had discontinued any antihypertensive treatment for at least 2 weeks prior to 
the study day. 
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Diabetic Patients 
A total of 95 patients (29 males, 66 females) with NIDDM were 
studied (Table 3.1). Of these, 26 patients (10 males, 16 females) were 
considered to be normotensive based on at least three normal readings of blood 
pressure. These patients were treated only with diet or oral hypoglycaemic 
agents, or both and were not on any other medications. A total of 69 
hypertensive NIDDM patients (19 males, 50 females) were recruited from the 
clinical trial. In this group of patients, 15 patients were receiving monotherapy 
with enalapril and 21 were treated with nifedipine alone. Another 4 enalapril-
treated patients and 11 nifedipine-treated patients required additional diuretic 
therapy (frusemide or indapamide). Among the patients receiving monotherapy 
with enalapril (n = 15) or nifedipine (n=21), a subset of 7 enalapril-treated and 
8 nifedipine-treated patients were restudied after withdrawal of their 
antihypertensive treatment for 2 weeks. 
3.3 DETERMINATION OF ERYTHROCYTE INTRACELLULAR SODIUM 
AND POTASSIUM CONCENTRATIONS (Na^JK-J 
3.3.1 Preparation of Erythrocytes 


































































































































































































1750 g for 10 minutes in a Jouan centrifuge at 4 C. The plasma and buffy 
coats were aspirated and the plasma used for determination of the 
biochemical indices. The erythrocytes were then washed three times with 
ice cold CWS to remove any trapped plasma. 
3.2 Preparation of Haemolysates 
In triplicate, 0.1 ml of the washed erythrocytes were lysed with 4.9 
ml of cesium chloride (1.5 mmol/1) and centrifuged at 1750 g for 10 
minutes. The haemolysates were used for the determination of intracellular 
concentrations of sodium and potassium. 
333 Determination of Sodium and Potassium Concentrations in Haemolysates 
The sodium and potassium concentrations in the haemolysates were 
determined by flame emission spectrometry (Model IL-943, Instrumentation 
Laboratories Inc, Lexington MA, USA). 
3,3.4 Determination of Haemoglobin Concentration in Haemolysates 
The haemoglobin concentration in the haemolysate was determined 
in a centrifugal analyser (Cobas-Bio™, Roche Diagnostica, Basle, 
Switzerland) following its conversion to cyanomethaemoglobin by 
Drabkin's reagent and using a haemoglobin standard dissolved in the same 
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reagent. 
3.3.5 Evaluation of Erythrocyte Intracellular Sodium and Potassium 
Concentrations 
The erythrocyte intracellular concentrations of sodium or potassium 
(mmol/l/rbc) were calculated using the following formula: 
[Na/K] in haemolysate x MCHC 
Na- /K- = — 
Hb concentration in haemolysate 
where [Na/K] is the sodium/potassium concentration, MCHC is mean 
corpuscular haemoglobin concentration, Hb is the haemoglobin (Dade & 
Lewis, 1984). 
3.4 DETERMINATION OF ERYTHROCYTE PASSIVE POTASSIUM 
EFFLUX 
Erythrocyte ouabain and bumetanide resistant passive effluxes were 
determined using the method of Garay et al (1981). When erythrocytes 
were incubated in an isotonic SFM containing ouabain and bumetanide to 
inhibit sodium pump and sodium-potassium cotransport maximally, the 
efflux of potassium from the erythrocytes into the incubation medium was 
considered the passive potassium efflux. 
4 0 
3 Determination of Potassium Concentrations in Supernatant 
The washed erythrocytes were resuspended in SFM-B to give a 
haematocrit of about 12.5-15% and kept on ice water. A total of 6 tubes 
were prepared in duplicate. 2 ml of SFM-B were added to each tube, 
followed by the addition of 0.5 ml of erythrocyte suspension and mixed 
well. The mixtures were incubated in a water bath at 37 C and removed at 
5 15 and 25 minutes. The mixtures were then transferred to ice water for 
1 minute and centrifuged at 1750 g for 10 minutes at 4 C. After 
centrifugation, the supernatant was carefully transferred to the another 
tubes. Potassium concentrations in the supernatant was determined by using 
flame atomic absorption spectrophotometry (Varian Techtron Pty Ltd, 
Melbourne, Australia, Model AA-1475). 
3.4.2 Evaluation of Passive Potassium Efflux 
For each of the incubations, a regression line of potassium 
concentration in the supernatant was plotted against time and the 
coefficients of regression (S) were calculated. The efflux rate of potassium 
from the erythrocytes (mmol/l/h/rbc) was calculated using the following 
formula: 
2.5 - (0.5 X HCT) 
Efflux rate of K=S x x 10'^  
0.5 X HCT 
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where 2.5 is the total volume of the incubation mixture (ml), 0.5 is the 
volume of the suspension, and HCT is the haematocrit of the suspension. 
The rate constant of passive potassium efflux was calculated by 
dividing the efflux rate by the intracellular potassium concentration. 
3.5 DETERMINATION OF ERYTHROCYTE SODIUM-LITHIUM 
COUNTERTRANSPORT (SLC) AND LITHIUM-POTASSIUM 
COTRANSPORT (LPC) 
Erythrocyte sodium-lithium countertransport and lithium-potassium 
cotransport were determined using the method similar to Canessa et al 
(1980a and 1989) and Smith et al (1984a). Sodium-potassium cotransport 
may be estimated by measurement of lithium-potassium cotransport since 
lithium can substitute for sodium in sodium-potassium cotransport. After 
the erythrocytes are loaded with lithium, the cells are incubated in an 
isotonic SCM containing ouabain which inhibits the sodium pump 
maximally. The overall efflux of lithium is therefore the sum of the 
activities of sodium-lithium countertransport, lithium-potassium cotransport, 
and the passive lithium leak. When the erythrocytes are incubated in an 
isotonic SFM containing ouabain to inhibit the sodium pump and sodium-
lithium countertransport maximally, the efflux of lithium is the combination 
of both the lithium-potassium cotransport and the lithium leak. The 
difference between the efflux rates in SCM (SLC+LPC+Li leak) and SFM 
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(LPC+Li leak) is therefore the sodium-lithium countertransport activity 
If SFM containing bumetanide (SFM-B) is used to inhibit the lithium-
potassium cotransport maximally as well, the efflux of lithium is solely due 
to the lithium leak. Thus, the difference in the efflux rates in SFM in the 
presence (LPC+Li leak) and absence of bumetanide (Li leak) is the 
lithium-potassium cotransport activity. 
3.5.1 Lithium Loading 
Lithium Loading Solution was added to the washed erythrocytes in 
a ratio of 1:4. The mixture was incubated for 3 hours in a shaking water 
bath at 37 C. After incubation, the erythrocytes were washed four times 
with ice cold CWS-0 to remove the extracellular lithium. 
3.5.2 Determination of Haematocrit 
The haematocrits of packed erythrocytes were determined using the 
microhaematocrit method (Autocrit II). 
3.5.3 Preparation of Haemolysates 
0.1 ml of erythrocytes were lysed with 4.9 ml of water in triplicate 
and centrifuged at 1750 g for 10 minutes. The haemolysates were used for 
the determination of intracellular concentrations of lithium (Ly . 
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Determination of the Lithium Concentration in Haemolysates 
The lithium concentration in the haemolysate was determined using 
flame atomic absorption spectrometry (Varian Techtron Pty Ltd, 
Melbourne, Australia, Model AA-1475). 
3 5 Determination of Lithium Efflux 
The remaining erythrocytes were resuspended in SFM to give a 
haematocrit of about 20-25% and kept in ice water. Three sets of tubes 
were prepared in duplicate. A total of 2 ml of SCM, SFM and SFM-B 
were added to the appropriate set of tubes, respectively, followed by the 
addition of 0.5 ml of the erythrocyte suspension to all sets of tubes and 
mixed well. The mixtures were incubated in a water bath at 37 C and 
removed at 10 30 60 minutes. The mixtures were then transferred to ice 
water for 1 minute and centrifuged at 1750 g for 10 minutes at 4 C. After 
centrifugation, the supernatant were transferred carefully to the another 
tubes. These supernatant were used for the determination of lithium 
concentration using flame atomic absorption spectrophotometry. 
3,5,6 Evaluation of Lithium Efflux Rate 
For each of the incubations, a regression line of lithium 
concentrations in the supernatant were plotted against time. The coefficients 
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of regressions (S) were calculated. The efflux rate of lithium from the 
erythrocytes (mmol/hour/l/rbc) was calculated using the following formula: 
2.5 - (0.5 X HCT) 
Efflux rate of Li=S x x 10"^  
0.5 X HCT 
where 2.5 is the total volume of the incubation mixture (ml), 0.5 is the 
volume of the suspension, and HCT is the haematocrit of the suspension. 
3.5.7 Evaluation of Intracellular Lithium Concentration 
The intracellular concentration of lithium (mmol/l/rbc) was 
calculated using the following formula: 
[Li] in haemolysate x 50 
Liie = 
HCT X 1000 
where [Li] is the lithium concentration, 50 is its dilution factor. 
The rate constants of sodium-lithium countertransport and lithium-
potassium cotransport were calculated by dividing their respective efflux 
rates by the intracellular lithium concentration. 
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3.6 VALIDATION OF METHODOLOGY FOR DETERMINATION OF 
ERYTHROCYTE SODIUM TRANSPORT SYSTEMS 
Effect of Time Course of Lithium Efflux 
The time courses of lithium efflux into the three media of SFM, 
SFM-B and SCM were investigated. Figure 3.1-3.3 show the results of 
lithium efflux from 4 healthy subjects. The efflux of lithium into the three 
media (SFM, SFM-B and SCM) was linear up to 2 hours, as reported 
previously by Smith et al (1984a). 
Intracellular Potassium Concentration and Its Effect on Ouabain- and 
Fnisemide-Resistant Passive Potassium Efflux 
Potassium efflux into a SFM-B medium from erythrocytes 
previously loaded with different concentrations of potassium using the 
pCMBS (2,5-p-chloromercuribenzene sulphonate) method (Garay et al, 
1981a) was investigated in two healthy subjects. Figure 3.4 (a, b) show the 
ouabain- and frusemide-resistant passive potassium effluxes which were 
found to be a linear function of the intracellular potassium concentration, 
as described previously by Garay et al (1981a). 
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3.7 PRESERVATION OF ERYTHROCYTES FOR DETERMINATION 
OF SODIUM TRANSPORT SYSTEMS 
The erythrocytes were washed three times with CWS. An equal 
volume of Preservative Solution was then added and the suspension gently 
mixed. The tube was carefully sealed and stored at 4 C prior to being 
assayed for the different ion transport systems. This erythrocyte 
preservation method allows the reliable determination of lithium efflux 
from erythrocytes stored up to 5 days after blood collection (Ostrow et al, 
1983). 
The sodium-lithium countertransport and lithium-potassium 
cotransport activity were determined on fresh and preserved erythrocytes 
(3 day old) in four subjects. The results are shown in Table 3.2. There 
were no significant deference between the two sets of sodium-lithium 
countertransport and lithium-potassium cotransport measurements. 
3.8 PRECISION OF THE METHODS 
The precision of the method is usually assessed by replicate 
determination of a sample and by calculating the mean and standard 
deviation of the estimates. The standard deviation divided by the mean and 
expressed as a percentage is the coefficient of variation of the method 
which is a measure of the precision of the method. In the absence of 
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sufficient material for multiple analyses, the precision can be determined 
by assaying a sufficient number of specimen in duplicate. The analytical 
standard deviation (SD) of the results of these duplicates were calculated 
according to the following formula: 
SD (SDdup)=V^Sd! 
2N 
where d is the difference between each duplicate and N is the number of 
duplicates (Broughton, 1978). 





where X is the mean value of all the specimens. 
The CV for sodium-lithium countertransport, lithium-potassium 
cotransport, passive potassium efflux, intracellular sodium and potassium 
concentrations are listed in Table 3.3. 
3.9 STATISTICS 
The raw data obtained from the experiments were entered into a 
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IBM personal computer, and the statistical analysis performed using the 
ABstat rel 6.01 software package. The Student's t-test was used to compare 
normally distributed data and the Mann-Whitney U-test used to compare 
skewed data. The Pearson's product moment correlation coefficient was 
used to assess the correlation between two variables. Paired t-tests or 
Wilcoxon's signed rank sum tests were used to assess the effects of 
treatment. The results are expressed as Mean SD or as Median (range) 
as appropriate. P values of less than 0.05 were considered to be significant. 
For multiple comparison, ANOVA or the Kruskal-Wallis one way analyses 
of variance was used. Bonferroni Theorom was used to calculate the 











































































































































































































































































































4.1 POPULATION CHARACTERISTICS 
The clinical features and biochemical indices of the four groups of 
subjects are shown in Table 4.1 where diabetic patients with hypertension 
are divided into patients with and without antihypertensive treatment. The 
patients with essential hypertension, NIDDM patients without hypertension, 
and NIDDM patients with hypertension (on or off antihypertensive 
treatment) were significantly older than the control subjects (pCO.Ol 
respectively). Compared to the control subjects, plasma creatinine 
concentrations were significantly higher in the NIDDM patients with 
hypertension who were not on antihypertensive treatment (p<0.01), while 
plasma urea concentrations were significantly higher in the NIDDM 
patients with hypertension who were receiving antihypertensive treatment. 
Creatinine clearances were significantly lower in the NIDDM patients with 
hypertension (with or without antihypertensive treatment) than in the 
control subjects (p<0.01). Plasma triglyceride concentrations were 
significantly higher in NIDDM (normotensive and hypertensive with or 
without antihypertensive treatment) patients (pCO.Ol). 
4.2 E R Y T H R O C Y T E I N T R A C E L L U L A R L I T H I U M 
CONCENTRATIONS AFTER LITHIUM LOADING 
After the erythrocytes were incubated with Lithium Loading 
Solution, the intracellular lithium concentrations in the control subjects, 
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patients with essential hypertension, and NIDDM patients with or without 
hypertension were similar. The median (range) values are 7.4(6.8-13.5), 
7.2(6.5-11.7), 7.8(6.7-9.1) and 7.3(6.6-11.5) mmol/1 rbc respectively. 
These intracellular concentrations of lithium, which were 12 fold higher 
than the concentration required to reach the half maximum rate (KJ of 
outward transport for lithium, ensured saturation of the sodium-lithium 
countertransport system. 
4.3 RELATIONSHIP BETWEEN ERYTHROCYTE ION TRANSPORT 
PARAMETERS AND OTHER VARIABLES 
Based on multiple linear regression, There was a significant 
correlation (p<0.01) between erythrocyte sodium-lithium countertransport 
activity and body mass index among the total subjects (n = 127; Figure 4.1). 
It made no difference to the correlation whether or the data was log 
transformed. However, there was no any significant correlation between 
ion transport parameters and clinical and biochemical indices when the 
patients treated with antihypertensive agents (enalapril or nifedipine) were 
excluded. There was a significant correlation (p<0.01) between 
erythrocyte sodium-lithium countertransport activity and supine diastolic 
blood pressure in non-diabetic subjects (n=32; Figure 4.2). Again, the 




















































































































































































































































































































































































































































































































































































































































g 41: Relationship between the erythrocyte sodium-lithium countertransport 
(SLC) and body mass index (BMI). 
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g 4.2: Relationship between the erythrocyte sodium-lithium countertransport 
(LPC) and supine diastolic blood pressure (SDBP). 
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ERYTHROCYTE SODIUM TRANSPORT SYSTEMS IN ESSENTIAL 
HYPERTENSION 
Between the 19 essential hypertensive patients and 13 control 
subjects, the sodium-lithium countertransport activity was significantly 
higher in the former compared with later (p< 0.01, Table 4.2). There were 
no significant differences in the other parameters. 
4.5 ERYTHROCYTE SODIUM TRANSPORT SYSTEMS IN PATIENTS 
WITH DIABETES MELLITUS 
Of the 44 NIDDM patients studied, 18 patients had hypertension but 
none of these patients was receiving any form of antihypertensive 
treatment. Compared to the control subjects (n = 13) the sodium-lithium 
countertransport activity was significantly higher (p<0.01) in the NIDDM 
patients (Table 4.3). 
4.5,1 NIDDM Patients without Hypertension 
Compared to the control subjects (n = 13), the sodium-lithium 
countertransport activity and intracellular sodium concentration were both 
significantly higher (pCO.Ol) in normotensive NIDDM patients (n=26). 
There was a tendency for lithium-potassium cotransport activity to be 
higher (p=0.06) in the normotensive NIDDM patients compared to the 
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control subjects. There were no significant differences in the other 
transport parameters (Table 4.4). 
4 2 NIDDM Patients with Hypertension 
The sodium-lithium countertransport activity was significantly 
higher in the hypertensive NIDDM patients (n = 18) than in the control 
subjects (n = 13; p<0.01). There were no significant differences in the 
other transport parameters between the 2 groups of subjects (Table 4.4). 
NIDDM Patients with and without Hypertension 
Compared to the hypertensive NIDDM patients, the normotensive 
NIDDM patients had a higher lithium-potassium cotransport activity 
(p<0.01), rate constant of the cotransporter (pCO.Ol) and intracellular 
sodium concentration (p<0.02). There were no significant differences in 
the other transport parameters between the NIDDM patients with and 
without hypertension (Table 4.4). 
4.6 ERYTHROCYTE SODIUM TRANSPORT SYSTEMS IN DIABETES 
MELLITUS PATIENTS WITH PROTEINURIA 
The normal daily urinary albumin excretion is <30 mg/24 hour. 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































27 NIDDM patients who had normal urinary protein excretion were 
studied. None of these patients was receiving other medication apart from 
oral hypoglycaemic agents. 
4 1 Clinical Features and Biochemistry Indices 
The clinical features and biochemistry indices of the studied groups 
of subjects are shown in Table 4.5 and 4.6. The NIDDM patients with and 
without proteinuria were significantly older than the control subjects 
(p<0.01). The supine systolic and erect systolic blood pressure were both 
significantly higher (p < 0.01) in the NIDDM patients with proteinuria than 
in the control subjects. Plasma triglyceride and glucose concentration were 
significantly higher (p<0.01) both in the NIDDM patients with and 
without proteinuria than in the control subjects. 
Compared to the NIDDM patients without proteinuria, the NIDDM 
patients with proteinuria had higher supine systolic (p<0.01) and erect 
systolic blood pressures (pCO.Ol). 
4,6.2 Ion Transport Systems and NIDDM Patients with Proteinuria 
The sodium-lithium countertransport activity and intracellular 
sodium concentration were significantly higher (p<0.05) in the NIDDM 
patients without proteinuria than in the control subjects. There were no 
68 
significant differences in the other transport parameters between the 2 
groups of subjects (Table 4.7). 
The sodium-lithium countertransport activity was significantly 
higher in the NIDDM patients with proteinuria than in the control subjects 
(p=0.01). There were no significantly differences in other transport 
parameters between the 2 groups of subjects (Table 4.7). 
The intracellular sodium concentration was significantly higher in 
the NIDDM patients without proteinuria than in those with proteinuria 
(p<0.05). There were no significant differences in the other parameters 
between the NIDDM patients with and without proteinuria (Table 4.7). 
4.7 EFFECTS OF TREATMENTS ON ERYTHROCYTE ION 
TRANSPORT SYSTEMS INDIABETIC HYPERTENSIVE PATIENTS 
4.7.1 Effects of Diuretic Therapy 
Of the 51 hypertensive NIDDM patients, 36 patients were treated 
with enalapril or nifedipine alone, while 15 patients required additional 
diuretic therapy (4 in the enalapril group and 11 in the nifedipine group). 
The blood pressure, plasma sodium concentration, urinary sodium excretion 
and urinary albumin excretion were similar in the 2 groups of patients. 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the transport parameters, although there was a tendency for lithium-
potassium cotransport activity to decrease in the patients treated in addition 
with diuretics (Table 4.8). 
7.2 Effects of Enalapril and Nifedipine Therapy 
There were 36 hypertensive NIDDM patients receiving monotherapy 
with enalapril (n = 15) or nifedipine (n=21) and no additional diuretic 
therapy. The lithium-potassium cotransport activity, rate constant of the 
lithium-potassium cotransporter, and intracellular concentration of sodium 
were all significantly higher (p<0.05) in patients treated with enalapril 
than those treated with nifedipine. There were no significant differences in 
other transport parameters between these 2 groups of patients. The blood 
pressure, plasma sodium concentration, urinary sodium excretion and 
urinary albumin excretion were also similar in the 2 groups of patients 
(Table 4.9). 
4.73 Effects of Enalapril Therapy 
Seven diabetic hypertensive patients receiving enalapril therapy were 
studied before and 2 weeks after the withdrawal of enalapril. The blood 
pressure and plasma sodium concentration were significantly lower when 
the patients were receiving enalapril therapy (p<0.01). However, the 
urinary sodium excretion remained the same. The lithium-potassium 
73 
cotransport activity, rate constant of the cotransporter and intracellular 
sodium concentration were significantly higher in the patients during 
treatment with enalapril. There were no significant differences in the other 
parameters (Table 4.10). 
7.4 Effects of Nifedipine Therapy 
Eight NIDDM patients with hypertension receiving monotherapy 
with nifedipine were studied before and after nifedipine was withdrawn for 
2 weeks. The supine systolic (p<0.05), supine diastolic (p<0.05), erect 
systolic (p<0.01) and erect diastolic (p<0.05) blood pressure all were 
significantly lower in the patients receiving nifedipine therapy. The 
transport parameters remained the same (Table 4.11). 
4.7*5 Comparison of the Effects of Enalapril and Nifedipine Therapy 
Comparing the patients receiving monotherapy with enalapril (n=7) 
and nifedipine (n = 8) revealed that the erythrocyte lithium-potassium 
cotransport activity (p=0.07), rate constant of lithium-potassium 
cotransport (p<0.05) and intracellular sodium concentration (p=0.05) 
were higher in the enalapril treated patients than the nifedipine treated 
patients. However, the plasma sodium concentration (p<0.05) was 
significantly lower in the enalapril treated patients than those treated with 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.1 SODIUM TRANSPORT IN ESSENTIAL HYPERTENSION 
5./. J Erythrocyte Sodium-Lithium Countertransport in Essential Hypertension 
Increased erythrocyte sodium-lithium countertransport activity was 
first reported in Caucasian patients with essential hypertension by Canessa 
et al (1980a). This was further confirmed by many other investigators 
(Canali et al, 1981; Woods et al, 1982; Carr et al, 1989). It has been 
reported that erythrocyte sodium-lithium countertransport activity was 
higher in normotensive whites than in normotensive blacks (Trevisan et al, 
1984; Smith et al, 1988). Furthermore, Canessa et al (1984b) and Weder 
et al (1984) reported that erythrocyte sodium-lithium countertransport 
activity was not increased in black patients with essential hypertension. A 
recent study by Arumanayagam et al (1987) showed that the erythrocyte 
sodium-lithium countertransport activity was higher in normotensive 
Chinese compared to European and non-Chinese Asians. These 
observations suggest that there are racial differences regarding the 
relationship between sodium-lithium countertransport and hypertension. The 
aim of the present study was to examine the possible associations between 
the various ion transport systems and hypertension (with and without 
diabetes) amongst Hong Kong Chinese subjects. 
Based on well established techniques (Canessa et al, 1980a; Smith 
et al, 1984a), these results have shown that amongst the Hong Kong 
8 1 
Chinese population, sodium-lithium countertransport activity was higher in 
patients with essential hypertension than in the control subjects, the 
normotensive control subjects had similar sodium-lithium countertransport 
activities to those reported by other investigators (Canessa et al, 1980a; 
Turner et al, 1985). Several environmental factors have been reported to 
influence sodium-lithium countertransport in human erythrocytes. Enhanced 
sodium-lithium countertransport activities can be induced by hypokalemia 
(Beuckelmann et al, 1985; Duhm & Behr 1986) hyperlipidaemia (Hunt 
et al, 1986; Carr et al, 1990b), obesity (McDonald et al, 1987; Persky et 
al 1990), oral contraceptives (Stokes et al, 1985; Beuckelmann et al, 
1985) and pregnancy (Worley et al, 1982; Wong et al, 1993) while 
exercise can reduce its activity (Woods et al, 1983; Adragna et al, 1985). 
In the present study, there were no significant differences in the body mass 
index plasma electrolytes, and lipid concentration between the patients 
with essential hypertension and control subjects. None of the female 
subjects were pregnant or on the oral contraceptive pill. Only Chinese 
subjects were studied, in order to eliminate the possibility of racial 
influences (Trevisan et al, 1984; Arumanayagam et al, 1987; Smith et al, 
1988). The sodium-lithium countertransport activity was not significantly 
related to age, plasma electrolytes, or lipid concentrations amongst either 
the subjects or the non-diabetic subjects (section 4.3). 
The relationship between sodium-lithium countertransport and blood 
pressure levels were controversial (Turner et al, 1985; Motulsky et al, 
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1987; Laurenzi & Trevisan 1989; Turner et al, 1989). However, in 
accordance with the findings of Canessa et al (1980a) the erythrocyte 
sodium-lithium countertransport was activity increased in the present study 
in patients with essential hypertension. There was a significant positive 
correlation between the sodium-lithium countertransport and supine 
diastolic blood pressure amongst the non-diabetic subjects (section 4.3), 
However, there was no direct relationship between sodium-lithium 
countertransport and blood pressure when all the subjects were analysed 
together. Sodium-lithium countertransport activity was not altered in 
secondary hypertension (Canessa et al, 1980a; Duhm & Behr 1986; 
Weder, 1990) inferring that increased sodium-lithium countertransport 
activity is not a consequence of high blood pressure per se. Although 
increased sodium-lithium countertransport activity has been related to the 
presence of a family history of hypertension (Canessa et al, 1980a; Canali 
et al, 1981; Woods et al, 1982; Can et al, 1989) the later was difficult to 
document accurately especially in this study population since most of the 
patients' parents were either deceased or lived in mainland China. 
However, results from this do suggest that increased erythrocyte sodium-
lithium countertransport activity may be a marker for essential hypertension 
in Chinese; as is the case in the Caucasian population. 
The clinical significance of the erythrocyte sodium-lithium 
countertransport system in humans is not clear, since lithium is not 
normally present under physiological conditions. This countertransport 
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system promotes a 1:1 sodium-sodium exchange, and does not have any 
effect on the internal ionic concentrations (Duhm & Becker, 1979; 
Mahnensmith & Aronson 1985; Weinberger et al, 1989). It has been 
suggested that sodium-lithium countertransport may just represent a 
functional mode of the plasma membrane sodium-hydrogen exchanger 
(Aronson 1982; Funder et al, 1984; Mahnensmith & Aronson 1985) and 
that they are probably mediated by the same transporter (Canessa et al, 
1987; Kahn et al, 1989). 
The increased activity of sodium-hydrogen countertransport may 
contribute towards the development of hypertension via the following 
mechanisms. In vascular smooth muscle cells, increased sodium-hydrogen 
countertransport causes the internal sodium concentration to rise, leading 
an increased internal calcium concentration through enhanced activity of the 
sodium-calcium exchanger. The increased internal calcium concentration 
will increase the resting vascular tone (Blaustein, 1977; Blaustein & 
Hamlyn, 1983). Additionally, a rise in the internal pH of vascular smooth 
muscle cells as the result of increased sodium-hydrogen countertransport 
can stimulate smooth muscle cell proliferation and further elevate the 
peripheral resistance (Funder et al, 1984; Aronson, 1988; Wray 1988). In 
proximal renal tubule, increased sodium-hydrogen countertransport can 
promote sodium reabsorption contributing further to the development of 
hypertension due to extracellular fluid volume expansion (Aronson, 1982; 
Mahnensmith & Aronson, 1985). It has been shown that increased sodium-
84 
lithium countertransport is inversely correlated with lithium clearance 
which provides an indirect measure of proximal tubular sodium excretion 
(Weder, 1986). 
5• 2 Erythrocyte Sodium-Potassium Cotransport in Essential Hypertension 
Abnormally low outward sodium-potassium cotransport has been 
observed in erythrocytes from patients with essential hypertension (Garay 
et al, 1980; Cusi et al, 1981; Smith et al, 1984b), although higher 
(Adragna et al, 1982; Smith et al, 1984b; Feig et al, 1985) or similar 
(Krzesinski & Rorive 1985b; Wiley et al, 1984) activities of sodium-
potassium cotransport have also been reported in some patients with 
essential hypertension. In this study, sodium-potassium cotransport activity 
among Chinese subjects with normal blood pressure and with essential 
hypertension was examined. 
Since lithium can replace sodium in the sodium-potassium 
cotransport system, lithium-potassium cotransport provide an indirect 
measurement of sodium-potassium cotransport. Indeed, lithium-potassium 
cotransport has been shown to correlate well with sodium-potassium 
cotransport (Canessa et al, 1982; Smith et al, 1984a). Based on the 
technique of Smith et al (1984a), the activity of lithium-potassium 
cotransport was similar between normotensive subjects and patients with 
essential hypertension. 
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To date, there has been little conclusive data regarding the 
significance of lithium-potassium cotransport. Cusi et al (1981) and Smith 
et al (1984b) reported that abnormality of the sodium-lithium 
countertransport might not necessarily be accompanied by that of sodium-
potassium cotransport. Therefore, it is possible that there is marked 
heterogeneity of sodium transport abnormalities among patients with 
hypertension (Canessa et al, 1981; Garay et al, 1983). Garay et al (1983) 
further suggested that among the patients with essential hypertension, there 
is a subgroup of subjects with decreased sodium-potassium cotransport, 
while another with increased sodium-lithium countertransport. Since 
essential hypertension is a complex polygenic disease with its 
manifestations being dependent on strong environmental components, it is 
not surprising that previous studies based on different patient populations 
have so far failed to demonstrate any definitive causal relationship between 
any one ion transport abnormality and the development of hypertension. 
Based on the findings of this study, it is possible that increased sodium-
lithium countertransport may play a more important pathophysiological role 
compared to sodium-potassium cotransport in Chinese patients with 
essential hypertension. 
5.1,3 Erythrocyte Intracellular Concentration of Sodium in Essential 
Hypertension 
The intracellular sodium concentration in human erythrocytes, like 
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all other cells, is lower than that in the extracellular fluid. It represents the 
final outcome of the activities of all membrane sodium transport systems 
and channels, via which sodium fluxes in both directions. Sodium efflux 
from the erythrocyte occurs primarily via four mechanisms: sodium pump, 
sodium-potassium cotransport, sodium-sodium countertransport (measured 
as sodium-lithium countertransport), and the ouabain- and frusemide-
insensitive sodium leak. Under physiological conditions, the sodium pump 
is the principal transporter, while sodium-sodium countertransport 
accomplishes no net transfer (Garay et al, 1983; Garay et al, 1987 Smith 
et al, 1988). 
Previous studies have yielded conflicting results on the relationships 
between internal sodium concentrations and essential hypertension. In some 
studies, sodium concentrations in erythrocyte have been found to be higher 
in patients with essential hypertension compared to normal subjects 
(Aderounmu & Salako 1979; Clegg et al, 1982; Zidek et al, 1985; 
Rahman et al, 1986). On the other hand, other studies failed to demonstrate 
such a difference (Weder et al, 1984; Weder et al, 1987; Stokes et al, 
1987; Smith et al, 1988). This study also showed that there was no 
significant difference in the erythrocyte intracellular sodium concentration 
between Chinese patients with essential hypertension and control Chinese 
subjects. Nonetheless, there was a trend towards a higher intracellular 
sodium concentration amongst the patients with hypertension. It is probable 
that defects in the membrane transport systems in the erythrocyte such as 
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increased activity of sodium-lithium countertransport may raise the 
intracellular concentration of sodium, this in turn, will increase the 
activities of other membrane transport systems such as the sodium pump 
and sodium-potassium cotransport in order to restore normal intracellular 
sodium levels. In the present study, the sodium pump activity was not 
measured, although there was increased sodium-lithium countertransport 
activity in patients with essential hypertension. This study failed to show 
a significant correlation between internal sodium concentration and lithium-
potassium cotransport or sodium-lithium countertransport. Smith et al 
(1988) reported a significant correlation between ouabain sensitive sodium 
efflux and internal sodium concentration both in normotensive and 
hypertensive subjects. They suggested that the internal sodium 
concentration is not determined by but instead may be a determinant of 
sodium pump activity. In particular, Saitta et al (1988) suggested that the 
sodium-potassium cotransport system may play two different roles in 
essential hypertension. These were as a 'defective second pump' in 
patients who have decreased cotransport affinity for internal sodium, or as 
a ‘compensatory second pump' in others, in whom abnormalities in the ion 
transport system may predispose the cells to a defective extrusion of excess 
intracellular sodium concentration. The sodium-potassium cotransport 
system may help the sodium pump extrude any excess intracellular sodium. 
More work is necessary to define the roles of the various transport systems 
and the mechanism by which sodium concentrations are maintained in 
human cells. 
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5 4 Erythrocyte Passive Potassium Efflux in Essential Hypertension 
A number of studies indicate that variations in cellular cation 
permeability may be genetically determined (Garay et al, 1980; Meyer et 
al 1981; Cooper et al, 1983; Smith et al, 1984b; Woods & Watson, 1984). 
In this context the erythrocyte ouabain- and frusemide-resistant passive 
sodium influx has been reported to be increased in patients with essential 
hypertension (Garay & Nazaret 1985; Garay et al, 1987). On the other 
hand Aderounmu and Salako (1979) have found that the erythrocyte 
ouabain- and frusemide-resistant passive potassium efflux was decreased in 
black patients with essential hypertension. The cross sectional nature of 
these studies and the lack of data on other ion exchange systems make it 
difficult to determine the significance of these findings. In the event of 
reduced membrane permeability, this may be a primary event in the 
initiation of hypertension. On the other hand, enhanced membrane 
permeability may merely represent a secondary phenomenon of increased 
intracellular sodium due to abnormalities in other ion exchange systems. 
The data from this showed that there were no significant difference 
in the ouabain- and frusemide-resistant passive potassium efflux between 
the control subjects and patients with essential hypertension. In addition, 
the ouabain- and frusemide-resistant passive potassium efflux was not 
significantly correlated with the intracellular or plasma potassium 
concentration. The preliminary results suggest that in essential hypertension 
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does not appear to be associated with abnormal passive potassium efflux in 
Chinese. 
SODIUM TRANSPORT SYSTEMS IN NON-INSULIN-DEPENDENT 
DIABETES MELLITUS (NIDDM) 
5.2./ Sodium-Lithium Countertransport in Non-Insulin-Dependent Diabetes 
Mellitus 
Hypertension and diabetes mellitus especially NIDDM are 
commonly associated. The prevalence of hypertension is about twice as 
higher amongst diabetic patients than that in the general population. The 
development of hypertension in insulin-dependent diabetic patients is 
frequently associated with diabetic nephropathy, while in NIDDM patients 
hypertension may either precede or follow the development of nephropathy. 
A genetic predisposition to essential hypertension may be a risk factor for 
the development of diabetic nephropathy (Weidmann & Ferrari, 1991; 
Weidmann et al, 1991). 
Increased activity of erythrocyte sodium-lithium countertransport 
may be a genetic marker for the development of essential hypertension 
(Canessa et al 1980; Canali et al, 1981; Woods et al, 1982; Carr et al, 
1989). It has also been reported to be increased in patients with insulin-
dependent diabetes mellitus (IDDM) who developed nephropathy 
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(Krokewski et al, 1988; Mangili et al, 1988). Furthermore, Can et al 
(1990a) found that sodium-lithium countertransport was increased in IDDM 
patients even before the onset of nephropathy and was associated with 
glomerular hyperfiltration. Thus, elevated sodium-lithium countertransport 
activity may be an early marker of diabetic nephropathy. However others 
reported that elevation of sodium-lithium countertransport was independent 
of the presence of nephropathy (Bunker & Bires, 1989; Jensen et al, 1990). 
It is interesting to note that Rutherford et al (1992) found that the affinity 
for sodium (KJ in the sodium-lithium countertransporter of IDDM patients 
remained normal, which was different from the situation in essential 
hypertension where the K^ for sodium was low (increased sodium affinity). 
Despite the high prevalence of NIDDM, hypertension and abnormal 
albuminuria among Hong Kong Chinese (Chan et al, 1993) little is known 
regarding the role of ion exchange systems in these patients. The results 
from this study has shown that erythrocyte sodium-lithium countertransport 
was higher in NIDDM patients (with and without hypertension) compared 
to the control subjects. However, amongst the NIDDM patients, the 
sodium-lithium countertransport was independent of hypertension or 
proteinuria. These findings are in agreement with Trevisan et al (1990) and 
Gall et al (1991) that sodium-lithium countertransport activity was elevated 
in NIDDM patients independent of hypertension or nephropathy. 
It is of note that the values of sodium-lithium countertransport 
9 1 
activity in the control subjects in this study was similar to those reported 
by other investigators (Canessa et al, 1980a; Turner et al, 1985). As 
indicated previously, different environmental factors can influence sodium-
lithium countertransport in human erythrocytes. In this regard, the body 
mass index was similar between the control subjects and diabetic patients. 
Multiple linear regression analysis revealed that sodium-lithium 
countertransport was not significantly correlated with age, plasma 
electrolytes concentrations or lipid concentrations amongst either the whole 
group of subjects or the control subjects, non-diabetic subjects, or diabetic 
patients alone. Furthermore, the elevated sodium-lithium countertransport 
was unlikely to be due to poor glycaemic control, as it was not significantly 
correlated with either haemoglobin A ,^ or plasma glucose concentration in 
NIDDM patients. 
Although it was demonstrated that increased erythrocyte sodium-
lithium countertransport in NIDDM patients, there was no relationship 
between this activity and blood pressure or proteinuria in Hong Kong 
Chinese with NIDDM. 
5.2.2 Erythrocyte Lithium-Potassium Cotransport and Intracellular Sodium 
Concentration in Non-Insulin-Dependent Diabetes Mellitus 
Although increased exchange body sodium has been reported in 
diabetic patients (Weidmann & Ferrari 1991; Weidmann etal, 1991), there 
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is a paucity of data regarding the lithium-potassium cotransport and 
intracellular sodium concentration in the erythrocytes of NIDDM patients. 
Trevisan et al (1988) reported that both normotensive and hypertensive 
NIDDM patients had similar sodium-potassium cotransport compared with 
non-diabetic controls. Within the diabetic patient population, hypertension 
does not seem to be associated with an abnormality in sodium-potassium 
cotransport. However, in the present study, it was shown that even in the 
absence of hypertension, the erythrocyte intracellular sodium concentration 
was increased in NIDDM patients. The presence of hypertension does not 
appear to increase further the lithium-potassium cotransport. These findings 
suggest that NIDDM is associated with abnormal intracellular accumulation 
of sodium even in the normotensive stage. 
Furthermore, it was found that the lithium-potassium cotransport 
activity tended to be higher in these normotensive NIDDM patients in this 
study. This tendency for the lithium-potassium cotransport activity to 
increase, indicated on increase in sodium-potassium cotransport activity, it 
may be a compensatory phenomenon secondary to increased intracellular 
sodium concentration. There was no significant relationship between 
intracellular sodium concentration and lithium-potassium cotransport 
activity in this study. The exact mechanism of increased intracellular 
sodium concentration in NIDDM is unclear. Possible sodium retaining 
mechanisms in NIDDM include increased glomerular filtration of glucose 
leading to enhanced proximal tubular sodium-glucose cotransport due to 
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hyperinsulinaemia (which activates several tubular sodium transport 
systems, along with other effects such as anti-natriuresis and stimulation of 
the sympathetic nervous system), an extravascular shift of fluid with 
sodium, and renal failure (Weidmann & Ferrari 1991). Apart from a 
simple equilibrium phenomenon, it is also possible that the increased 
activity of sodium-lithium countertransport thought to genetically 
determined may represent a functional mode of sodium-hydrogen 
countertransport (Aronson, 1982; Funder et al, 1984; Mahnensmith & 
Aronson, 1985). The intracellular sodium concentration represents the 
resultant Na+ channel cotransport activity. Moreover, the intracellular 
sodium concentration is affected by insulin. Stimulation of the sodium 
pump activity will produce a decrease, whereas activation of the sodium-
hydrogen countertransport, calcium-sodium countertransport, and sodium-
aminoacid cotransport systems tend to increase the intracellular sodium 
concentrations (Weidmann & Ferrari 1991). However, the regulating 
mechanisms of these various ion exchange systems, which are highly 
complex and probably genetically determined, remain to be elucidated. To 
date, the situation in NIDDM is still poorly understood. In view of the 
important role of intracellular sodium concentration in the pathogenesis of 
hypertension, more studies are required in these aspects. 
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5.3 EFFECT OF ANTIHYPERTENSIVE AGENTS ON ERYTHROCYTE 
SODIUM TRANSPORT SYSTEMS 
In this study, both enalapril and nifedipine significantly reduced 
blood pressure in NIDDM patients with hypertension. In addition to blood 
pressure reduction, enalapril induced a significant increase in both internal 
sodium concentration and lithium-potassium cotransport activity in the 
erythrocytes. On the other hand, neither the sodium-lithium 
countertransport nor passive potassium efflux were affected by enalapril or 
nifedipine. 
Sanchez et al (1991) reported that enalapril increased sodium-
potassium cotransport and sodium pump activities, and decreased sodium 
concentration in erythrocytes in patients with essential hypertension. They 
further concluded that enalapril could increase sodium-potassium 
cotransport and sodium pump activities by preventing the effects of 
endogenous inhibitors or altering the number of transport proteins on cell 
membranes. The findings from this study of increased sodium concentration 
following enalapril treatment is therefore in contrast to those of Sanchez et 
al (1991). The mechanism by which enalapril enhances the internal sodium 
concentration and lithium-potassium cotransport in the erythrocytes of 
NIDDM patients with hypertension is unclear. The results from this study 
showed that urinary sodium excretion was not affected by enalapril, though 
the plasma sodium concentration was decreased during enalapril treatment. 
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It is suggested that the elevation of intracellular sodium concentration may 
be secondary to the alteration of cellular cation permeability by enalapril. 
The increase in lithium-potassium cotransport activity may represent a 
compensatory phenomenon for the excess intracellular sodium 
concentration. On the other hand, atrial natriuretic factor (ANF) 
concentrations have been reported to be increased in diabetic patients with 
hypertension (Sawicki et al, 1988; Weidmann et al, 1991). In this regard, 
angiotensin converting enzyme inhibitor has been shown to interfere with 
the natriuretic effect of ANF. Regarding the effects of treatment on 
sodium-lithium countertransport, the results from this study also agrees 
with previous studies showing that this is not significantly affected by any 
antihypertensive treatment (Adragna et al, 1982; McDonald et al, 1987; 
Laurenzi & Trevisan, 1989). 
In conclusion, sodium-lithium countertransport activity is increased 
in Chinese patients with essential hypertension. It is also increased in the 
NIDDM patients, which is independent of hypertension or proteinuria. In 
addition, erythrocyte intracellular sodium concentration is increased in the 
NIDDM patients. Treatment with enalapril increases the erythrocyte 
intracellular sodium concentration. 
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